Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Ellipta device
Time to teach and ease of use for the Ellipta device
Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a LABA and a long-acting muscarinic antagonist (LAMA).1
Where do GOLD and NICE recommend LAMA/LABA and ICS/LAMA/LABA classes within UK indications?2,3
Adapted visual shows, for only GOLD group B and NICE guidance for patients with no asthmatic features or features suggesting steroid responsiveness, the initial and follow-up treatment recommendations.
Access clinical evidence and practical guidance for appropriate patients
Resources for COPD management
References:
- Trelegy Ellipta Summary of Product Characteristics.
- COPD in over 16s: diagnosis and management NICE guideline [NG115]. Last updated: July 2019.
- GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2026 Report
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.
August 2026 | PM-GB-FVU-WCNT-260007 (V1.0)
